(1986), Megaloblastic anaemia due to vitamin B12 deficiency caused by small intestinal bacterial overgrowth: possible role of vitamin B12 analogues
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
However, there may be enough information from the history and physical examination that an MRI is not need by an experienced physician
These peptides remain options for individuals who cannot access Ipamorelin but are generally not preferred for Tirzepatide stacking
Supporting gut barrier integrity with BPC-157 could reduce one known trigger of autoimmune activation
